Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations
- Author:
Aristides K. MANIATIS
1
;
Michael P. WAJNRAJCH
;
Marc THOMAS
;
Sung Beom CHUNG
;
Jieun LEE
Author Information
- Publication Type:Review Article
- From:Annals of Pediatric Endocrinology & Metabolism 2025;30(1):11-16
- CountryRepublic of Korea
- Language:English
- Abstract: Growth hormone (GH) is crucial for childhood growth and body composition. In pediatric GH deficiency (pGHD), the pituitary gland fails to produce sufficient GH, which affects linear growth in childhood. pGHD is conventionally treated with daily recombinant human GH (rhGH); however, because GH therapy lasts throughout childhood, adherence to daily rhGH treatment can be low, resulting in suboptimal effectiveness. Somatrogon is a long-acting GH analog designed to address the challenges associated with daily GH therapy for pGHD. Somatrogon administered once per week is a potential alternative to daily GH therapy. The use of somatrogon is supported by phase II and III clinical trials demonstrating that once-weekly injections are noninferior to once-daily somatropin injections in terms of efficacy, safety, and tolerability and have the advantage of reduced treatment burden. This review summarizes the clinical trials of somatrogon and discusses the therapeutic profile and effects of treating pGHD with reduced injection frequency.
